Placebo patients to be offered Algeta's Alpharadin after efficacy in cancer trial
This article was originally published in Scrip
Executive Summary
Contrary to expectation, Norway's Algeta is stopping a pivotal Phase III trial of its lead product candidate, the anticancer Alpharadin (radium-223 chloride), so that patients in the placebo arm can be offered the treatment.